Example: quiz answers

American Thoracic Society

American Thoracic Society Am J Respir Crit Care Med Vol 163. pp 283 291, 2001 Internet address: International Consensus Conferences in Intensive Care Medicine: Noninvasive Positive Pressure Ventilation in Acute Respiratory Failure O RGANIZED J OINTLY BY THE A MERICAN T HORACIC S OCIETY , THE E UROPEAN R ESPIRATORY S OCIETY , THE E UROPEAN S OCIETY OF I NTENSIVE C ARE M EDICINE , AND THE S OCI T DE R ANIMATION DE L ANGUE F RAN AISE , AND APPROVED BY THE ATS B OARD OF D IRECTORS , D ECEMBER 2000 Noninvasive positive pressure ventilation (NPPV) was appliedfirst to patients with chronic pulmonary disease but is now be-ing used to support those with acute respiratory failure (ARF).

American Thoracic Society 285 patient training and education, personnel time, and capital equipment as well as other direct and indirect health care ex-

Tags:

  American, Society, Thoracic, American thoracic society

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Transcription of American Thoracic Society

1 American Thoracic Society Am J Respir Crit Care Med Vol 163. pp 283 291, 2001 Internet address: International Consensus Conferences in Intensive Care Medicine: Noninvasive Positive Pressure Ventilation in Acute Respiratory Failure O RGANIZED J OINTLY BY THE A MERICAN T HORACIC S OCIETY , THE E UROPEAN R ESPIRATORY S OCIETY , THE E UROPEAN S OCIETY OF I NTENSIVE C ARE M EDICINE , AND THE S OCI T DE R ANIMATION DE L ANGUE F RAN AISE , AND APPROVED BY THE ATS B OARD OF D IRECTORS , D ECEMBER 2000 Noninvasive positive pressure ventilation (NPPV) was appliedfirst to patients with chronic pulmonary disease but is now be-ing used to support those with acute respiratory failure (ARF).

2 An International Consensus Conference in Intensive CareMedicine considering the role of NPPV in ARF was held inParis, France, from April 13 14, 2000; sponsored by the Criti-cal Care Assembly of the American Thoracic Society (ATS),the European Respiratory Society (ERS), the European Soci-ety of Intensive Care Medicine (ESICM), and the Soci t deR animation de Langue Fran aise (SRLF).The methods of the Consensus were established by the Na-tional Institutes of Health (1) and adapted subsequently foruse in critical care medicine (2). Briefly, the process com-prised four phases.

3 First, five key questions were formulatedby the scientific advisors designed to address issues integral tothe evaluation of noninvasive ventilatory support in its currentand future roles. Second, a comprehensive literature searchwas performed and key articles precirculated to a jury of 10clinician scientists who were not experts in the field under dis-cussion. Third, authorities in NPPV selected by the Organiz-ing Committee and scientific advisors delivered focused pre-sentations during a two-day symposium attended by the juryand about 150 delegates.

4 Each presentation was followed bydebate and discussion. Finally, the jury summarized the avail-able evidence in response to the questions over the two daysimmediately after the the purposes of this report, NPPV was defined as anyform of ventilatory support applied without the use of an en-dotracheal tube, and was considered to include continuousc positive airway pressure (CPAP), with or without inspiratorypressure support; volume- and pressure-cycled systems, pro-portional assist ventilation (PAV), and adjuncts such as theuse of helium oxygen (heliox) gas mixtures.

5 The term acuterespiratory failure (ARF) was considered to include patientswith acute lung injury (ALI) and acute respiratory distresssyndrome (ARDS), those with acute exacerbations of obstruc-tive airflow limitation ( , asthma and COPD); acutely dec-ompensated patients with the obesity hypoventilation syn-drome (OHS) and cardiogenic pulmonary edema (CPE);patients developing ARF in the perioperative period; andthose with either difficulty weaning from invasive mechanicalventilatory support, or in whom endotracheal intubation (ETI)was considered inappropriate.

6 The information presented tothe jury was designed to address the following five questions. QUESTION 1: WHAT ARE THE RATIONALE, POTENTIAL BENEFITS, AND GOALS FOR NPPV? Patients require ventilatory assistance to reduce the Pa CO2 (Fig-ure 1) and/or to improve oxygenation (Figure 2). If they canreceive appropriate noninvasive ventilatory assistance, pa-tients are spared the discomfort and risks associated with en-dotracheal intubation (ETI). Although studies suggest thatNPPV is associated with a reduced incidence of nosocomialpneumonia, methodological problems mandate reinvestiga-tion of this issue.

7 Potential benefits must be balanced againstthe discomfort of a nasal or facial mask and risks specific toNPPV ( , failure to provide sufficient oxygenation or CO 2 elimination, eye or nasal trauma, gastric distension/aspiration).The goals of NPPV differ depending upon the clinical con-text. During acute decompensations of asthma or COPD, thegoal is to reduce CO 2 by unloading the respiratory musclesand augmenting alveolar ventilation, thereby stabilizing arte-rial pH until the underlying problem can be reversed. Whenemployed during episodes of hypoxemic ARF the goal is toensure an adequate Pa O2 until the underlying problem can bereversed.

8 When applied continuously to patients with chronicventilatory failure the goal of NIPPV is to provide sufficientoxygenation and/or CO 2 elimination to sustain life by revers-ing atelectasis or resting the respiratory muscles. When ap-plied intermittently to patients with OHS, the goal is to limitsleep- and position-induced adverse changes in oxygenationand CO 2 elimination and their pathophysiological sequelae bystenting the upper airway, increasing lung volume, and aug-menting alveolar ventilation. In cardiogenic pulmonary edema,the goal of NPPV is to improve oxygenation, reduce work ofbreathing, and increase cardiac output.

9 Jury and coauthors : Timothy W. Evans (London, UK, Chairman ), Richard K. Albert(Denver, CO), Derek C. Angus (Pittsburgh, PA), Julian F. Bion (Birmingham, UK),Jean-Daniel Chiche (Paris, France), Scott K. Epstein (Boston, MA), Jean YvesFagon (Paris, France), Marco Ranieri (Pisa, Italy), Jacob Iasha Sznajder (Chicago,IL), Antoni Torres (Barcelona, Spain), Keith R. Walley (Vancouver, BC, Canada). Consensus Conference Organization : Scientific Advisors: Nicholas Hill (Providence,RI), Laurent Brochard (Paris, France). International Consensus Conference Committee : ATS: Arthur Slutsky (Toronto, ON,Canada), Catherine Sassoon (Long Beach, CA); ERS: Antoni Torres (Barcelona,Spain); ESICM: Francois Lemaire (Creteil, France), Graham Ramsay (Maastrict,Netherlands); SRLF: Jordi Mancebo (Barcelona, Spain), Christian Richard (Paris,France).

10 The conference was funded in part by an unrestricted educational grant fromRespironics, article is copublished and copyrighted by American Journal of Respiratory andCritical Care Medicine , Intensive Care Medicine , and R animation . 284 American JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 163 2001 Determining whether NPPV Is a Valuable Approachin Clinical Practice The clinical and physiologic rationales for NPPV suggest it mayhave advantageous ( , avoidance of ETI), and/or disadvanta-geous ( , failure to provide adequate gas exchange) , NPPV may decrease ( , reduced requirement forICU) or increase ( , costs of staff training/education and pa-tient contact time) resource utilization.


Related search queries